Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2021, with a specific reporting date of July 14, 2021. The document serves as a transaction notification under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. It details share transactions executed by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the company. It exclusively reports on specific share transactions.
| Instrument | Transaction Date | Price | Total Volume | Exchange |
|---|---|---|---|---|
| Ordinary Shares (GBP) | 2021-07-12 | £14.2600 | Multiple transactions (e.g., 2,292 for CEO) | London Stock Exchange (XLON) |
| American Depositary Shares (USD) | 2021-07-12 | $39.9700 | Multiple transactions (e.g., 1,285 for CSO) | New York Stock Exchange (XNYS) |
Material Changes
The filing reports an increase in notional interest in GSK securities for multiple executives. These increases resulted from the re-investment of dividends paid to shareholders on July 8, 2021, into the Company's Deferred Annual Bonus Plan. There are no material changes to the company's business operations, financial condition, or capital structure reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, risk factors, contingencies, or unusual items. It is a routine regulatory disclosure of insider trading activity.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were automatic re-investments of dividends into the Deferred Annual Bonus Plan, not open-market purchases or sales by executives.
- Participants: Transactions involved senior leadership including the CEO (Ms E Walmsley), CSO (Dr H Barron), CFO (Mr I Mackay), and other SVPs.
- Share Prices: The execution price was £14.2600 for Ordinary Shares and $39.9700 for ADSs on July 12, 2021.
- Financial Data: This document does not provide quarterly or annual financial performance data; investors must refer to Form 20-F or earnings releases for revenue and profit metrics.